Anzeige
Mehr »
Login
Montag, 15.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QC0X | ISIN: US12529R1077 | Ticker-Symbol:
NASDAQ
15.04.24
21:59 Uhr
6,860 US-Dollar
-0,550
-7,42 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
C4 THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
C4 THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur C4 THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiC4 Therapeutics, Inc.: C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum2
08.04.C4 Therapeutics, Inc.: C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Me56WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
► Artikel lesen
06.03.Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m17
04.03.US STOCKS Avidity, C4 Therapeutics, Avadel Pharma3
04.03.C4 Therapeutics rises on license agreement with Merck KGaA7
04.03.C4 Therapeutics, Inc.: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins224Collaboration Focused on Two Targeted Protein Degraders from C4T's Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research...
► Artikel lesen
04.03.C4 Therapeutics, Inc. - 8-K, Current Report1
27.02.UBS cuts C4 Therapeutics stock target to $18, maintains Buy7
22.02.C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans3
22.02.C4 Therapeutics, Inc. - 10-K, Annual Report2
22.02.C4 Therapeutics, Inc. - 8-K, Current Report1
22.02.C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights605CFT1946 Preclinical Data Accepted for a Poster Presentation at the AACR Annual Meeting 2024 Phase 1 Dose Escalation Trials for CFT7455 and CFT1946 Continue to Progress; Data from Both Trials Expected...
► Artikel lesen
15.02.C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?2
29.01.JP Morgan upgrades C4 Therapeutics to neutral, cites pipeline8
29.01.Analyst Expectations For C4 Therapeutics' Future5
10.01.C4 Therapeutics gains on restructuring plan4
09.01.C4 Therapeutics sheds nearly 30% of workforce; shares up7
09.01.C4 Therapeutics, Inc.: C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines175Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused...
► Artikel lesen
09.01.C4 Therapeutics, Inc. - 8-K, Current Report2
04.01.C4 Therapeutics, Inc.: C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals400WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
► Artikel lesen
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1